FGF Family: From Drug Development to Clinical Application

• Published in: International journal of molecular sciences Vol. 19; no. 7; p. 1875
• Main Authors: Hui, Qi, Jin, Zi, Li, Xiaokun, Liu, Changxiao, Wang, Xiaojie
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.06.2018; MDPI
• Subjects: Amino acids; Angiogenesis; Animals; Bile; Binding sites; Cholesterol; Classification; Clinical Trials as Topic; Disease; Drug development; Drug Discovery; Endoplasmic reticulum; Fibroblast Growth Factors - metabolism; Fibroblasts; Glucose; Growth factors; Heparan sulfate; Humans; Laboratories; Ligands; Metabolism; Peer review; Peptides; Pharmaceuticals; Phylogenetics; Phylogeny; Proteins; Receptors, Fibroblast Growth Factor - metabolism; Review; Vitamin D; Wound healing; drug development; fibroblast growth factor receptor inhibitor; clinical application; wound healing; fibroblast growth factor; metabolic regulation
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms19071875

Fibroblast growth factor (FGF) belongs to a large family of growth factors. FGFs use paracrine or endocrine signaling to mediate a myriad of biological and pathophysiological process, including angiogenesis, wound healing, embryonic development, and metabolism regulation. FGF drugs for the treatment of burn and ulcer wounds are now available. The recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in maintaining homeostasis of bile acid, glucose, and phosphate further extended the activity profile of this family. Here, the applications of recombinant FGFs for the treatment of wounds, diabetes, hypophosphatemia, the development of FGF receptor inhibitors as anti-neoplastic drugs, and the achievements of basic research and applications of FGFs in China are reviewed.